Amicus Therapeutics - Stock Price History | FOLD

Historical daily share price chart and data for Amicus Therapeutics since 2021 adjusted for splits. The latest closing stock price for Amicus Therapeutics as of September 24, 2021 is 10.87.
  • The all-time high Amicus Therapeutics stock closing price was 24.89 on December 22, 2020.
  • The Amicus Therapeutics 52-week high stock price is 25.39, which is 133.6% above the current share price.
  • The Amicus Therapeutics 52-week low stock price is 8.60, which is 20.9% below the current share price.
  • The average Amicus Therapeutics stock price for the last 52 weeks is 14.04.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Amicus Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 14.2237 9.5500 24.8900 6.6300 23.0900 137.06%
2019 11.2103 10.0400 14.4000 7.4800 9.7400 1.67%
2018 13.8221 15.1600 17.1200 8.3800 9.5800 -33.43%
2017 10.3500 5.1300 16.2400 5.1300 14.3900 189.54%
2016 6.9360 9.0300 9.3500 4.5300 4.9700 -48.76%
2015 11.4110 8.6100 18.2300 5.9500 9.7000 16.59%
2014 4.2658 2.4100 8.6100 1.8200 8.3200 254.04%
2013 2.7800 2.8400 4.2200 1.9700 2.3500 -12.31%
2012 5.2648 3.5700 6.8800 2.5300 2.6800 -22.09%
2011 5.3292 4.5600 7.9400 2.1000 3.4400 -26.81%
2010 3.4267 3.8400 4.8000 1.9500 4.7000 18.39%
2009 7.9094 8.0000 12.2700 3.3600 3.9700 -50.25%
2008 11.2884 10.3400 17.9500 7.5000 7.9800 -25.77%
2007 13.8496 14.4300 18.0400 9.5400 10.7500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.959B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71